Cardiac hypertrophy: Targeting Raf/MEK/ERK1/2-signaling

International Journal of Biochemistry and Cell Biology

Volumn 41, Issue 12, 2009, Pages 2351-2355

  Lorenz, Kristina ^a   Schmitt, Joachim P ^a   Vidal, Marie ^a   Lohse, Martin J ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cardiac hypertrophy; ERK1 2; Signaling

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RAF PROTEIN;

AUTOPHOSPHORYLATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; LOSS OF FUNCTION MUTATION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; SHORT SURVEY; TRANSGENIC MOUSE;

EID: 70350336225     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2009.08.002     Document Type: Short Survey

References (32)

1. Aoki Y., Niihori T., Narumi Y., Kure S., and Matsubara Y. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat 29 (2008) 992-1006
2. Bueno O.F., De Windt L.J., Tymitz K.M., Witt S.A., Kimball T.R., Klevitsky R., et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19 (2000) 6341-6350
3. Depold E.P., Schmitt J.P., Patlak J.B., Beck S.E., Moore J.R., Seidman J.G., et al. Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap assay. Am J Physiol Heart Circ Physiol 293 (2007) H284-H291
4. Esposito G., Rapacciuolo A., Naga Prasad S.V., Takaoka H., Thomas S.A., Koch W.J., et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105 (2002) 85-92
5. Frey N., Katus H.A., Olson E.N., and Hill J.A. Hypertrophy of the heart: a new therapeutic target?. Circulation 109 (2004) 1580-1589
6. Gutkind J.S., and Offermanns S. A new Gq-initiated MAPK-signaling pathway in the heart. Dev Cell 16 (2009) 163-164
7. Harris I.S., Zhang S., Treskov I., Kovacs A., Weinheimer C., and Muslin A.J. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 110 (2004) 718-723
8. Heineke J., and Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7 (2006) 589-600
9. Hill J.A., and Olson E.N. Cardiac plasticity. N Engl J Med 358 (2008) 1370-1380
10. Hindley A., and Kolch W. Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases. J Cell Sci 115 (2002) 1575-1581
11. Kontaridis M.I., Yang W., Bence K.K., Cullen D., Wang B., Bodyak N., et al. Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways. Circulation 117 (2008) 1423-1435
12. Lorenz K., Schmitt J.P., Schmitteckert E.M., and Lohse M.J. A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med 15 (2009) 75-83
13. Luttrell D.K., and Luttrell L.M. Signaling in time and space: G protein-coupled receptors and mitogen-activated protein kinases. Assay Drug Dev Technol 1 (2003) 327-338
14. Mathew J., Sleight P., Lonn E., Johnstone D., Pogue J., Yi Q., et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104 (2001) 1615-1621
15. Mikula M., Schreiber M., Husak Z., Kucerova L., Ruth J., Wieser R., et al. Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. EMBO J 20 (2001) 1952-1962
16. Mitchell S., Ota A., Foster W., Zhang B., Fang Z., Patel S., et al. Distinct gene expression profiles in adult mouse heart following targeted MAP kinase activation. Physiol Genomics 25 (2006) 50-59
17. Munzel F., Muhlhauser U., Zimmermann W.H., Didie M., Schneiderbanger K., Schubert P., et al. Endothelin-1 and isoprenaline co-stimulation causes contractile failure which is partially reversed by MEK inhibition. Cardiovasc Res 68 (2005) 464-474
18. Muslin A.J. MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (Lond) 115 (2008) 203-218
19. Nakamura T., Colbert M., Krenz M., Molkentin J.D., Hahn H.S., Dorn II G.W., et al. Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. J Clin Invest 117 (2007) 2123-2132
20. Owens D.M., and Keyse S.M. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26 (2007) 3203-3213
21. Pandit B., Sarkozy A., Pennacchio L.A., Carta C., Oishi K., and Martinelli S. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 39 (2007) 1007-1012
22. Purcell N.H., Wilkins B.J., York A., Saba-El-Leil M.K., Meloche S., Robbins J., et al. Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci USA 104 (2007) 14074-14079
23. Raman M., Chen W., and Cobb M.H. Differential regulation and properties of MAPKs. Oncogene 26 (2007) 3100-3112
24. 2+ blockers prevent myocardial remodeling induced by chronic NO inhibition in rats. Hypertension 41 (2003) 963-967
25. Schmitt J.P., Debold E.P., Ahmad F., Armstrong A., Frederico A., Conner D.A., et al. Cardiac myosin missense mutations cause dilated cardiomyopathy in mouse models and depress molecular motor function. Proc Natl Acad Sci U S A 103 (2006) 14525-14530
26. Sheikh F., Raskin A., Chu P.H., Lange S., Domenighetti A.A., Zheng M., et al. An FHL1-containing complex within the cardiomyocyte sarcomere mediates hypertrophic biomechanical stress responses in mice. J Clin Invest 118 (2008) 3870-3880
27. Slupsky J.R., Quitterer U., Weber C.K., Gierschik P., Lohse M.J., and Rapp U.R. Binding of Gbetagamma subunits to cRaf1 downregulates G-protein-coupled receptor signalling. Curr Biol 9 (1999) 971-974
28. Wang Y. Mitogen-activated protein kinases in heart development and diseases. Circulation 116 (2007) 1413-1423
29. Yamaguchi O., Watanabe T., Nishida K., Kashiwase K., Higuchi Y., Takeda T., et al. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest 114 (2004) 937-943
30. Yue T.L., Wang C., Gu J.L., Ma X.L., Kumar S., Lee J.C., et al. Inhibition of extracellular signal-regulated kinase enhances ischemia/reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res 86 (2000) 692-699
31. Zheng M., Dilly K., Dos Santos Cruz J., Li M., Gu Y., Ursitti J.A., et al. Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart. Am J Physiol Heart Circ Physiol 286 (2004) H424-H433
32. Zhai P., Gao S., Holle E., Yu X., Yatani A., Wagner T., et al. Glycogen synthase kinase-3α reduces cardiac growth and pressure overload-induced cardiac hypertrophy by inhibition of extracellular signal-regulated kinases. J Biol Chem 282 (2007) 33181-33191